Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Pletal
Revasc, generically known as cilostazol, is a medication primarily used to improve symptoms of intermittent claudication, a condition characterized by pain in the legs during exercise due to reduced blood flow. It belongs to a class of drugs called phosphodiesterase 3 inhibitors, which work by widening blood vessels and preventing platelet aggregation, thereby increasing blood flow to the extremities. Revasc is typically prescribed for patients with peripheral artery disease (PAD).
For improving symptoms of intermittent claudication due to peripheral artery disease.
Outcome:
Increased cilostazol levels
Mechanism:
Inhibition of CYP3A4 metabolism
Outcome:
Increased cilostazol levels
Mechanism:
CYP2C19 inhibition
Outcome:
Increased bleeding risk
Mechanism:
Additive antiplatelet effect
Most likely new formulation: Extended-release formulation (Year 2025, 60% confidence)
Based on current usage trends and clinical trial data, there is a low (5%) likelihood of any major regulatory changes in the next 2 years.
Phosphodiesterase 3 Inhibitor, Antiplatelet Agent, Vasodilator
Quinolinone